Skip to main content


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

Voclosporin

Voclosporin-API

CAS Number: 515814-01-4

Therapeutic Category
Others
API Technology
Synthetic
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Under-Development
Innovator Brand (USA)
Lupkynis
Plant
IPDO

Mechanism of Action

Voclosporin is an immunosuppressant drug that works by inhibiting the activity of an enzyme called calcineurin. Calcineurin is involved in the activation of T cells, which are a type of white blood cell that play a key role in the immune system.

In individuals with autoimmune diseases such as lupus nephritis, the immune system mistakenly attacks healthy tissues and organs, causing inflammation and damage. Voclosporin works by blocking calcineurin and therefore inhibiting the activation of T cells, which helps to reduce the inflammation and prevent tissue damage.

In addition to its immunosuppressive effects, voclosporin has also been shown to have antiproliferative and anti-inflammatory effects, which may contribute to its ability to improve outcomes in patients with lupus nephritis.

It is important to note that while voclosporin can be effective in controlling the symptoms of autoimmune diseases, it can also suppress the immune system, making patients more susceptible to infections. As with any medication, the benefits and risks of voclosporin should be carefully weighed by a healthcare provider before it is prescribed.

Indication

Voclosporin is indicated for the treatment of certain autoimmune diseases, specifically for the treatment of lupus nephritis. Lupus nephritis is a type of kidney disease that occurs in people with systemic lupus erythematosus (SLE), a chronic autoimmune disease in which the body's immune system attacks its own tissues and organs.

Voclosporin is used in combination with another immunosuppressant, mycophenolate mofetil, to improve kidney function and reduce the risk of kidney failure in patients with lupus nephritis.

It is important to note that the safety and effectiveness of voclosporin may vary depending on individual circumstances and that patients should consult their healthcare provider to determine if voclosporin is appropriate for their treatment. Additionally, patients taking voclosporin may require monitoring for potential side effects and drug interactions.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Voclosporin API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Voclosporin API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Contact Us

Please fill in the following form for API Requirement & we'll get back to you shortly

We are here to help, if you have any country specific requirements.

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.